← Back to Screener
ScreenerNewsCompareWatchlist
VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesNewsEarningsCompareWatchlist
AnalyzeValuationTotal ReturnDCA CalculatorInsider Activity
HomeStocksZVSARevenue History
OverviewPriceRevenueEarningsP/ERatiosDividendTargets

ZVSA logoZyVersa Therapeutics, Inc. (ZVSA) Revenue History

Annual and quarterly revenue from 2020 to 2025

TTM Revenue
$0
0
YoY Growth
-100.0%
Declining
Latest Quarter
$0
Q4 2025
QoQ Growth
-

Compound Annual Growth Rate (CAGR)

3-Year-
5-Year-
10-Year-
Highest Annual Revenue$0 (0)
Highest Quarter$26K (Q4 2024)

Loading revenue history...

ZVSA Revenue Growth

1-Year Growth
-100.0%
Declining
3-Year CAGR
-
5-Year CAGR
-
10-Year CAGR
-
TTM vs Prior Year-
Peak Annual Revenue$0 (0)

Download Historical Data

6 records • Includes OHLCV + Technical Indicators (MA50, MA200, RSI)

Free sign in required to download data

ZVSA Revenue Analysis (2020–2025)

As of May 15, 2026, ZyVersa Therapeutics, Inc. (ZVSA) generated trailing twelve-month (TTM) revenue of $0, reflecting significant decline in growth of -100.0% year-over-year. The most recent quarter (Q4 2025) recorded $0 in revenue.

Looking at the longer-term picture, ZVSA's historical revenue data shows various trends over time.

ZVSA Historical Revenue Data (2020–2025)

Showing 6 of 6 records
Year Revenue YoY % Gross Profit Gross Margin Op. Income Op. Margin
2025$0-$0-$-6,844,787-
2024$0-$-6,933-$-9,136,834,000-
2023$0-$-10,400-$-14,420,774-
2022$0-$-10,400-$-13,833,132-
2021$0-$-10,400-$-7,704,376-
2020$0-$-10,400-$-11,833,058-

See ZVSA's True Return

Price is only half the story. See total return with reinvested dividends.

Launch Calculator

Is ZVSA Undervalued?

DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.

View Valuation

Compare ZVSA vs DBVT

Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..

Start Comparison

ZVSA — Frequently Asked Questions

Quick answers to the most common questions about buying ZVSA stock.

Is ZVSA's revenue growth accelerating or slowing?

ZVSA revenue declined -100.0% year-over-year, contrasting with the 5-year CAGR of N/A. TTM revenue fell to $0.00. This reverses the prior growth trend.

What is ZVSA's long-term revenue growth rate?

ZyVersa Therapeutics, Inc.'s 5-year revenue CAGR of N/A reflects the variable expansion pattern. Current YoY growth of -100.0% is below this long-term average.

How is ZVSA's revenue distributed by segment?

ZVSA reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2020-2025 are available for download. Segment mix reveals concentration and diversification trends.

VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Income statements. Balance sheets. Cash flows.

Data updated daily

Quick Links

  • Home
  • Screener
  • Themes
  • Market Valuation
  • Valuation
  • Compare
  • Total Return
  • DCA Calculator
  • Earnings Calendar
  • Earnings Today
  • Earnings Hub
  • News
  • Insights
  • Methodology
  • How It Works
  • Profile

Popular Screens

  • Value Stocks
  • Quality Compounders
  • Growth Stocks
  • Dividend Stocks
  • Undervalued Stocks
  • Momentum Stocks
  • High Free Cash Flow

Community

  • Follow @VCPScanner on X

Get weekly stock ideas — free

© 2026 VCP Scanner. All rights reserved.
About·Privacy Policy·Terms of Service
Not financial advice. Do your own research.

ZVSA Revenue Over Time (2020–2025)